Supplemental Figure 1 Summary of patient disposition in the open-label and double-blind periods.



Number of patients (%) included in predictor analyses in open-label period

Remission endpoint in open-label period	ETN 50 mg + MTX (*N* = 834)
DAS28 remission induction	763 (91)
SDAI remission induction	755 (91)
CDAI remission induction	762 (91)

Number of patients (%) included in predictor analyses in double-blind period

Remission endpoint in double-blind period	ETN 50 mg + MTX (*n* = 201)	ETN 25 mg + MTX (*n* = 201)	MTX monotherapy (*n* = 197)
Loss of DAS28 remission (± change in DAS28 ≥0.6)	163 (81)	160 (80)	158 (80)
Loss of SDAI remission	72 (36)	60 (30)	53 (27)
Loss of CDAI remission	74 (37)	66 (33)	56 (28)

CDAI Clinical Disease Activity Index, *DAS28* Disease Activity Score based on a 28-joint count, *ETN* etanercept, *LDA* low disease activity, *MTX* methotrexate, *QW* once weekly, *SDAI* Simplified Disease Activity Index.